- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback